Most Read Articles
01 Oct 2020
There is not enough irrefutable evidence that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists have positive effects on cognition in patients with type 2 diabetes mellitus (T2DM), according to a study.
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 28 Mar 2019

The addition of the GLP-1* analogue semaglutide to SGLT-2** inhibitors improved glycaemic control and weight loss in patients with type 2 diabetes (T2D) poorly controlled with SGLT-2 inhibitors alone, according to results of the international, phase IIIb SUSTAIN 9*** trial.

Product Highlight - Cresemba

09 Dec 2020
Presentation:
Cap: Each capsule contains 100 mg isavuconazole (as 186.3 mg isavuconazonium sulfate).
Inj: Each vial contains 200 mg isavuconazole (as 372.6 mg isavuconazonium sulfate).

Indication: CRESEMBA is indicated in adults for the treatment of:
- invasive aspergillosis
- mucormycosis in patients for whom amphotericin B is inappropriate

Dosage & Administration:
Cap: Loading dose: 2 cap (equiv to 200 mg) every 8 hr for first 48 hr (total administrations: 12 cap in 48 hrs). Maintenance dose: 2 cap (equiv to 200 mg) once daily, starting 12-24 hr after the last loading dose. CRESEMBA capsules can be taken with or without food. 
CRESEMBA capsules should be swallowed whole. Do not chew, crush, dissolve or open the capsules.

IV infusion: Loading dose: 1 vial every 8 hr for 1st 48 hr (total administrations: 6 vial in 48 hrs).
Maintenance dose: 1 vial once daily, starting 12-24 hr after the last loading dose.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Oct 2020
There is not enough irrefutable evidence that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists have positive effects on cognition in patients with type 2 diabetes mellitus (T2DM), according to a study.
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 28 Mar 2019

The addition of the GLP-1* analogue semaglutide to SGLT-2** inhibitors improved glycaemic control and weight loss in patients with type 2 diabetes (T2D) poorly controlled with SGLT-2 inhibitors alone, according to results of the international, phase IIIb SUSTAIN 9*** trial.